Is JNJ Overvalued? DCF Says Worth $127

gurufocus.com · 2026-10-12

On October 12, 2026, we conducted a DCF analysis for Johnson & Johnson (JNJ), a company that has shown notable price performance over the past year. The stock h

TickrTrends take: Johnson & Johnson's intrinsic value according to discounted cash flow analysis stands at 127 dollars per share, which aligns with TickrTrends' current assessment that the stock is overvalued. For valuation-focused investors, the gap between the DCF-derived worth and JNJ's market price represents the key metric to monitor as earnings reports and interest rate changes could shift the assumptions underlying this valuation model. Given the Healthcare sector's sensitivity to regulatory and clinical developments, watchers should pay particular attention to how pipeline progress and patent expirations affect the company's projected cash flows.

Read the full story at gurufocus.com →